Neurocrine Biosciences Starts Phase 1 Study on NBI-1117567 in Healthy Adults

Neurocrine Biosciences, Inc., based in San Diego with the stock symbol NBIX on Nasdaq, has announced the start of its Phase 1 clinical trial for NBI-1117567. This investigational compound is an oral, M1/M4 selective muscarinic agonist, with a preference for M1, aimed at potentially treating neurological and neuropsychiatric conditions. The study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the compound in healthy adult participants.

Dr. Eiry W. Roberts, Chief Medical Officer at Neurocrine Biosciences, emphasized the company's extensive muscarinic portfolio. She highlighted that NBI-1117567, as an M1-preferring M1/M4 agonist, could be particularly beneficial in addressing cognitive symptoms for patients struggling with conditions that may also involve psychosis.

NBI-1117567 targets muscarinic receptors, which are essential for activating brain signaling pathways. The human brain contains five types of muscarinic acetylcholine receptors, two of which—M1 and M4—are selectively targeted by this compound. M1 has been identified as a potential target for cognitive enhancement, while M4 is associated with psychosis. Neurocrine Biosciences secured the rights to develop and commercialize NBI-1117567 from Nxera Pharma, previously known as Sosei Heptares.

Neurocrine Biosciences is a prominent biopharmaceutical company focused on neuroscience, with a mission to alleviate suffering for patients with significant unmet needs. The company is committed to developing transformative treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio includes FDA-approved therapies for conditions such as tardive dyskinesia, Huntington's disease-associated chorea, endometriosis, and uterine fibroids, the latter two in collaboration with AbbVie. Additionally, the company has a robust pipeline featuring multiple compounds in various stages of clinical development.

For the past 30 years, Neurocrine Biosciences has leveraged its deep understanding of neuroscience and the complex interactions between the brain and body to tackle challenging conditions. Their ongoing dedication is evident in their relentless pursuit of innovative medicines to reduce the burden of debilitating diseases and disorders. Neurocrine Biosciences champions "brave science," as reflected in their registered trademark and company slogan.

The company continues to make strides in the biopharmaceutical industry, driven by a commitment to improving the lives of those affected by severe neurological and neuropsychiatric conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!